Fortress Biotech (FBIO) Accumulated Expenses (2010 - 2021)

Fortress Biotech's Accumulated Expenses history runs 12 years deep, the most recent figure standing at $82.9 million for Q3 2021.

• In Q3 2021, Accumulated Expenses rose 292.08% year-over-year to $82.9 million; the TTM figure through Sep 2021 stood at $82.9 million (up 292.08% YoY), while the FY2020 annual figure was $45.4 million, up 4255.95% from the prior year.
• Accumulated Expenses for Q3 2021 stood at $82.9 million, up from $59.9 million in the prior quarter.
• The five-year high for Accumulated Expenses was $82.9 million in Q3 2021, with the low at $1.0 million in Q1 2019.
• The 5-year median for Accumulated Expenses is $16.4 million (2018), against an average of $20.9 million.
• The sharpest annual moves came in 2019 and 2020: Accumulated Expenses tumbled 94.16% in 2019, then jumped 4255.95% in 2020.
• Fortress Biotech's Accumulated Expenses stood at $17.6 million in 2017, then dropped by 7.21% to $16.4 million in 2018, then tumbled by 93.63% to $1.0 million in 2019, then surged by 4255.95% to $45.4 million in 2020, then soared by 82.54% to $82.9 million in 2021.
• Business Quant data shows FBIO's Accumulated Expenses at $82.9 million in Q3 2021, $59.9 million in Q2 2021, and $27.8 million in Q1 2021.